Oncolytics Biotech submits Orphan Designation to EMA for treatment of ovarian, pancreatic cancers

NewsGuard 100/100 Score
Dec 22 2014

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced that it has submitted applications for Orphan Designation to the European Medicines Agency ("EMA") for REOLYSIN® for the treatment of pancreatic and ovarian cancers.

"This is the second jurisdiction in which we have elected to file for Orphan Designation," said Dr. Brad Thompson, President and CEO of Oncolytics. "The EMA serves all 28 member countries of the EU and securing Orphan Designation would help support the future development of REOLYSIN® in the region."

Source:

Oncolytics Biotech Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: , , ,

Comments (0)

Suggested Reading

Survey highlights misconceptions on sun protection and skin cancer prevention
Aspirin shows no benefit in preventing breast cancer recurrence, study finds
Medically aided conception vs. natural conception: Study explores cancer risk in children
Unlocking glioblastoma's immune suppression mechanism
Amgen plows ahead with costly, highly toxic cancer dosing despite FDA challenge
What is the association between post-diagnostic plant-based dietary patterns and the risk of prostate cancer progression?
Gut microbiome study challenges established cancer biomarkers, identifies new bacterial links to colorectal cancer
Breast Cancer Now funds new research to investigate how breast cancer cells survive and grow

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study finds major gaps in cancer screening use in Federally Qualified Health Centers